Cargando…
Reimbursement policy optimization for Angiotensin-converting enzyme (ACE) inhibitors in Bulgaria: Controlling expenditure without undermining access to treatment
Autores principales: | Kazakov, Rossen M, Petrova, Penka I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603611/ http://dx.doi.org/10.1186/2052-3211-8-S1-P17 |
Ejemplares similares
-
Availability and reimbursement of biological products for severe asthma in Bulgaria
por: Milushewa, Petya, et al.
Publicado: (2020) -
Analysis of Healthcare Expenditures in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022) -
The angiotensin-converting enzyme (ACE) gene family of Anopheles gambiae
por: Burnham, Susan, et al.
Publicado: (2005) -
Angiotensin converting enzyme gene polymorphism and influence of ACE inhibition
por: Arman, Q.
Publicado: (2010) -
Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome
por: Gómez, Juan, et al.
Publicado: (2020)